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Edited by Jacomine Krijnse-LockerAbstract This study provides evidence that proteasomal activ-
ity is required at multiple steps in human cytomegalovirus repli-
cation. Electron microscopy revealed that no viral particles were
assembled in the presence of proteasome inhibitor MG132.
Immunoﬂuorescence and Western blot analyses using MG132
demonstrated that immediate early gene expression was sup-
pressed at low but not high MOI. In contrast, expression of late
proteins was completely blocked independent of MOI. Addition-
ally, pulsed-ﬁeld gel electrophoresis demonstrated that MG132
interferes with cleavage of HCMV DNA. Bromodeoxyuridine
incorporation studies showed that de novo viral DNA synthesis
is reduced in the presence of MG132. Furthermore, in contrast
to previous hypotheses we demonstrated that neither the ND10
components PML and hDaxx nor NFjB activation represent
the target for MG132.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Viruses have evolved multiple strategies to take over host
cell pathways and promote viral replication. The ubiquitin-
proteasome system (UPS) seems to be a cellular pathway that
viruses utilize for their own beneﬁt. Previous studies have re-
ported that proteasome inhibitors block replication of various
viruses by targeting diﬀerent steps of the replication cycle. For
example, it has been demonstrated that proteasome inhibitors
prevent translocation of inﬂuenza virus to the nucleus [1]. In
the case of HSV-1, proteasome inhibitors decreased immediate
early and late protein expression [2]. Watanabe et al. reported
that paramyxovirus maturation is blocked by proteasome
inhibitors [3], while the UPS aﬀects budding events of rhabdo-
viruses [4] and HIV [5]. Pro¨sch et al. recently discussed the
suppression of HCMV replication and virus induced immuno-
modulation by proteasome inhibitors [6].
HCMV has a sequential regulation of viral gene expression,
leading to induction and repression cycles occurring in the imme-
diate early (IE), early (E) and late phase (L) of viral replication.
IE1and IE2 induce expressionof earlyproteins,mediateG1/S cell
cycle arrest and host replication shut-oﬀ [7,8]. Early genes pre-*Corresponding author. Fax: +49 30 450 525907.
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doi:10.1016/j.febslet.2008.01.040dominantly encode viralDNAreplication factors, repair enzymes
or immune evasion proteins, and induce the expression of L genes
[9,10]. L proteins down-regulate expression of E genes and are
mainly involved in virion assembly. HCMV DNA replication is
thus the key step in maturation of new virions. In this report we
characterize the impact of proteasome inhibition on viral protein
expression. We also investigate the inﬂuence of MG132 on viral
DNA replication and virion assembly.2. Materials and methods
2.1. Cells and viruses
Human embryonic lung ﬁbroblasts (HELF) were grown in Eagles
minimum essential medium supplemented with 2% fetal calf serum
(FCS), 2 mM L-glutamine, 1 mM sodium pyruvate, 1· non-essential
amino acids and gentamicin sulfate (50 lg/ml). Stably transduced hu-
man foreskin ﬁbroblasts (HFF) were grown in Dulbeccos Modiﬁed
Eagles Medium supplemented with 10% FCS, L-glutamine (350 lg/
ml), gentamicin sulfate (10 lg/ml) and puromycin (5 lg/ml). Infection
of cells with HCMV AD169 was carried out as described previously
[9]. Proteasome inhibitors were added after adsorption.
2.2. Proteasome inhibitors
MG132 and lactacystin (Calbiochem) were dissolved in 95% (w/v)
EtOH and DMSO respectively. Stock solutions were stored at
20 C before use. Cell toxicity (CC50) of MG132 and lactacystin were
determined for HELF using the Cell Proliferation Kit II (Roche)
according to the manufacturers recommendation.
2.3. Construction of a recombinant HCMV
The virus mutant HB5D NFjB lacking the four NFjB binding sites
within the major immediate early (MIE) enhancer/promoter was con-
structed in two steps from the AD169 BACmid pHB5 [11] using pro-
cedures described previously [12]. For construction of pHB5-BACmid
pHB5DIEtet a PCR fragment was generated from the contiguous
primers AZ-IE-tet1 (5 0ACGTACCGTGGCACCTTGGAGGAAG-
GGCCCTCGTCAGGATTATCAGGGTCCATCTTTCTCCCAGT-
GAATTCGAGCTCGGTAC-3 0) and AZ-IE-tet2 (5 0ACGGGGTC-
ATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATA-
ACTTACGGTAAATGACCATGATTACGCCAAGCTCC-3 0). The
PCR fragment containing a tetracycline resistance gene was inserted
into pHB5 by homologous recombination in Escherichia coli, replacing
the IE region between nucleotides 173678 and 175159 (AD169 se-
quence) by the tetracycline resistance gene. The 4773 bp SmaI–EcoRI
fragment from pCM5801 containing the 11 kb EcoRI-J fragment of
AD169 representing the IE region including the MIE enhancer/
promoter was subcloned into pUC19 generating plasmid pIESE. A
SacI–BglI fragment from p18mut containing the enhancer region in
which the four putative NFjB binding sites were destroyed by site di-
rected mutagenesis was cloned into pIESE. The newly generated plas-
mid was designated pIED18. The insert was isolated by EcoRI–SmaI
digest and recloned in pET-21d (Novagen) generating pET-IEDNFjB.blished by Elsevier B.V. All rights reserved.
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into the BamHI cleaved shuttle mutagenesis vector pST76KSR. The
mutated MIE region from plasmid pST76KSR-IEDNFjB was inserted
into pHB5DIEtet by two-step homologous recombination [13] result-
ing in BAC pHB5DNFjB. Recombinant clones were isolated after
selection on tetracycline containing agar plates. Mutagenesis of BAC
pHB5DNFjB was validated by restriction analysis and sequencing of
the MIE region, conﬁrming the deletion of NFjB binding sites. Re-
combinant virus was reconstituted by transfection of MRC-5 using
Superfect reagent (Qiagen).
2.4. Immunoﬂuorescence
HELF (1 · 105) were grown on cover slips, infected at MOI 0.1 or 1
and treated with 0.5 lM MG132 or left untreated. At 72 h p.i. cells
were ﬁxed with 3% paraformaldehyde [14]. Staining for IE1, pUL44
and MCP was performed using mAbs p63-27, BS510 and 28-4, respec-
tively, for 45 min at RT prior to incubation with Cy3-labeled goat anti-
mouse F(ab 0)2 fragments for 45 min. Nuclei were stained using DAPI
(1 lg/ml). Samples were mounted in Fluoroprep (bioMerieux) contain-
ing 2.5% (w/v) 1,4-diazabicyclo[2.2.2]octan and examined using an
Olympus BX 50 ﬂuorescence microscope. Images were captured with
an Olympus Colorview II camera in conjunction with the Cell D soft-
ware program (Olympus).
2.5. BrdU labeling and immunostaining
HELF (1 · 105) were grown on cover slips, infected at MOI 1 and
treated with 0.05–0.5 lM MG132 or left untreated. BrdU (10 lM)
was added at 45 h p.i. Cells were ﬁxed at 72 h p.i. and DNA was dena-
tured in 2 N HCl for 30 min at 37 C followed by neutralization with
1· TBE. Immunostaining was performed using mAb a-BrdU (Diano-
va) for 45 min at RT prior to incubation with Cy3-labeled goat anti-
mouse F(ab 0)2 fragments. Nuclei were stained using DAPI (1 lg/ml).
Samples were mounted as described above and analyzed using a Zeiss
Laser Scanning Microscope LSM 510/ConfoCor2. Images were pro-
cessed using the Axioplan software program (Zeiss).
2.6. Proteasome activity assay
Cell extracts of HELF (1 · 106) were prepared using lysis buﬀer
(20 mM Tris-HCl pH 7.5, 1 mM EDTA, 1 mM dithiothreitol,
50 mM NaCl, 0.1% NP40) followed by sedimentation of cell frag-
ments. Supernatant was treated with protease inhibitor cocktail
(Roche). Chymotrypsin-like proteasome activity was determined using
the substrate Succ-LLVY-AMC (Bachem). Cell extracts were incu-
bated for 30 min with assay buﬀer (20 mM Tris–HCl pH 7.5, 1 mM
EDTA) containing 50 lM substrate. Released AMC was detected
using a ﬂuorometer (BioTek Instruments) in conjunction with the
KC4 software program. Proteasome activity was calculated as ﬂuores-
cence units/30 min/lg protein.
2.7. Plaque reduction assay
HELF (5 · 105) were seeded in 12-well plates and infected at MOI
0.001. After adsorption the inoculum was replaced with semisolid
medium containing 0.05–0.5 lM MG132. At day 7 p.i. cells were
stained with mAb p63-27 against IE1 for 1 h at 37 C prior to incuba-
tion with HRP-conjugated anti-mouse F(ab 0)2 fragments for 2 h.
Nuclei of infected cells were visualized using the AEC Staining Kit
(Sigma). Plaques were counted using a light microscope.
2.8. SDS–PAGE and Western blot
Extracts from mock-infected or HCMV infected HELF (1 · 106; dif-
ferent MOI) treated with 0.5 lM MG132 or left untreated were sepa-
rated on 10% polyacrylamide gels, transferred onto nitrocellulose
membranes and subjected to Western blot analysis. Membranes were
incubated with mAbs E13, BS510, 27-156, 28-4 and 58-15 against
IE1/IE2, pUL44, gB, MCP and pp65, respectively, prior to incubation
with HRP-conjugated anti-mouse F(ab 0)2 fragments. Detection of pro-
tein bands was performed using ECL reagent (Pierce). Membranes
were re-probed for b-actin to verify equal loading.
2.9. Pulsed-ﬁeld gel electrophoresis (PFGE)
HELF (1 · 106) were seeded in 25 cm2 ﬂasks, infected at MOI 1, trea-
ted with 0.05–0.5 lMMG132 or left untreated and prepared for PFGE
as described previously [15]. Samples and Lambda Ladder PFGMarker(New England Biolabs) were loaded into a 1%LMP agarose gel for elec-
trophoresis (15–110 s, 150 V, 27 h). Upon completion of electrophoresis
DNA was stained with 1 lg/ml ethidium bromide and photographed.
2.10. Thin sectioning and electron microscopy
HELF(1 · 106)were seeded in 25 cm2ﬂasks and infected atMOI1 in the
presence or absence of 0.5 lM MG132. Cells were ﬁxed at 72 h p.i. and
embedded as described before [13]. Sectionswere analyzed using a Tecnai
G2 (FEI Company, Eindhoven) electron microscope operated at 120 kV.3. Results
3.1. Increased 20 S proteasome activity in HCMV infected
HELF
To characterize 20 S proteasome activity in HCMV infected
cells, HELF were infected at MOI 0.05–2 and treated with
0.5 lMMG132 for 72 h or left untreated beforemeasuring protea-
some activity. An increased MOI was linked to increased protea-
some activity (Fig. 1A). In the presence of MG132 proteasome
activity was reduced by 70–80% at all MOIs examined (Fig. 1A).
This experiment demonstrated that in HCMV infected cells, activ-
ity of the 20 S proteasome increases in anMOI-dependent fashion.
3.2. 20 S proteasome activity is required for HCMV replication
For determination of IC50 values plaque assays were carried
out. The mean IC50 values were 0.165 lM for MG132 and
13.530 lM for lactacystin (Table 1), demonstrating that
HCMV replication is strongly inhibited by MG132 and less se-
verely suppressed by lactacystin (Fig. 1B). Both compounds
have a CC50 value 4- to 10-fold higher than the IC50 value
(Table 1), suggesting that suppression of viral replication was
not due to cytotoxic side eﬀects of the drugs.
To assure that the observed anti-HCMV eﬀect of MG132 is
indeed due to proteasome inhibition and not the result of inhi-
bition of other cellular proteases, we carried out plaque assays
using calpain inhibitor I or II (both inhibit calpain I and II,
cathepsin B and L). Fig. 1C shows that HCMV replication
was not suppressed by both calpain inhibitors, indicating that
blocking these cellular proteases does not contribute to the
antiviral eﬀect of proteasome inhibitors.
3.3. 20 S proteasome activity is required at multiple stages of the
replication cycle
To determine the stage of viral replication that is sensitive to
proteasome inhibition we analyzed the eﬀect of time-delayed
drug addition. HELF were infected at MOI 0.001 and
MG132 (0.5 lM) was added at diﬀerent times p.i. At day 7
p.i. viral replication was examined using plaque assays. If
MG132 was added after adsorption (0 h p.i.) viral replication
was inhibited by 95% (Fig. 1D). Addition of MG132 at 24 h
or 48 h p.i. resulted in suppression of viral replication by
82% or 91%, respectively. If the drug was added at 72 h p.i.
viral replication was reduced by 52%. Addition of MG132 at
96 h p.i. had no eﬀect on HCMV replication. This experiment
suggests that all stages of the viral replication cycle are sensi-
tive to proteasome inhibition to diﬀerent extents.
3.4. Inhibition of infectious particle formation by proteasome
inhibitors
To investigate the formation of viral particles under protea-
some inhibition, electron microscopy of infected HELF (MOI
Table 2
Nuclear capsids of infected cells in the absence or presence of 0.5 lM
MG132
Virus Number of nuclei counted Number of capsid
form per nucleus
(%)
A B C
AD169 15 15.5 36.9 47.6
AD169 + MG132 17 0.0 0.0 0.0
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Fig. 1. Analysis of 20 S proteasome inhibitors. (A) Analysis of 20 S proteasome activity in HCMV infected HELF. HELF were infected at MOI
0.05–2 and treated with 0.5 lM MG132 for 72 h (MG132) or left untreated (w/o) before measuring proteasome activity. (B and C) Inﬂuence of
calpain and proteasome inhibitors on HCMV replication. HELF were infected at MOI 0.001 and analyzed for viral replication in the presence of (B)
MG132 or lactacystin or (C) calpain inhibitor I or II using plaque assays. (D) Time-of-addition analysis of MG132. HCMV-infected HELF (MOI
0.001) were treated with 0.5 lMMG132 beginning from diﬀerent time points p.i. (0–96 h). At day 7 p.i. cells were analyzed for viral replication using
plaque assays. Error bars represent ± S.D. of three independent experiments.
Table 1
Antiviral activities of proteasome inhibitors
Compound Mean IC50 (lM) Mean CC50 (lM)
Plaque reduction Cell proliferation
MG132 0.165 1.05
Lactacystin 13.530 57.00
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out. All types of capsids (A-, B- and C-capsids; Table 2, Sup-
plementary data) were found in the nuclei of untreated cells.
Additionally, infectious particles and dense bodies were ob-
served in the cytoplasm or in the extracellular space (Supple-
mentary data). In contrast, MG132 treated cells did not
show any viral particles (Table 2, Supplementary data), indi-
cating that viral replication did not occur. These experiments
suggested that MG132 prevents formation of viral particles.
3.5. Inﬂuence of MG132 on HCMV protein expression
Since MG132 completely suppressed formation of infectious
progeny virus we wanted to characterize the impact of protea-some inhibition on IE, E and L protein expression. Cover slip
cultures were infected at MOI 0.1 and 1.0, respectively, in the
presence or absence of 0.5 lM MG132 prior to immunoﬂuo-
rescence staining at 72 h p.i.
Expression and distribution of viral proteins changed in the
presence of MG132. At low MOI the number of IE1-positive
cells was strongly reduced. However, the level of IE1 expres-
sion in these cells was comparable to the level achieved in
the absence of the inhibitor. Additionally, distribution of
pUL44 changed from replication compartments [16] into a
pp65
gB
IE2
IE1
MOI 0.5 MOI 1 MOI 2
- + - + - +
UL44
Actin
pp65
mock MOI 0.1 MOI 0.25
- + - + - +
gB
IE1
UL44
MCP
IE2
MG132
MG132
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Moreover, a complete loss of MCP expression was observed
(Fig. 2). Consistent with this MCP was no longer detectable
in MG132 treated cells infected at high MOI (Fig. 2). Again,
pUL44 accumulated in pre-replication compartments
(Fig. 2). However, the expression of IE1 remained widely un-
changed at high MOI.
To further characterize the inﬂuence of MG132 on viral pro-
tein expression at diﬀerent MOIs, extracts of mock- or HCMV
infected HELF (MOI 0.1–2) treated with 0.5 lM MG132 or
left untreated were subjected to Western blot analysis. At
MOI 0.1 the expression of IE, E and L proteins was clearly
inhibited by MG132 (Fig. 3). However, at higher MOI (MOI
0.5–2) expression of IE1 was no longer aﬀected by proteasome
inhibition, while IE2 expression levels were slightly reduced up
to MOI 1 (Fig. 3). In contrast, expression of gB and MCP
was completely inhibited at all MOIs examined (Fig. 3).
Additionally, expression of pUL44 was strongly suppressed
by MG132 at both low and high MOI (Fig. 3). Levels of
pp65 were clearly reduced up to MOI 0.5 and gradually in-
creased at higher MOIs but did not reach the level expressed
in the untreated control (Fig. 3).
These experiments revealed that the observed inhibition of
infectious particle formation by MG132 is due to complete
suppression of L protein expression. Furthermore, these data
demonstrated that expression of IE and E proteins is reduced
at low MOI. However, the eﬀect of MG132 on IE protein
expression was abolished at high MOI.
3.6. Inﬂuence of MG132 on cleavage of concatenated DNA
To analyze the structure of viral DNA accumulated in the
presence of increasing concentrations of MG132 (0.05–IE1
w/o
UL44
MG132
MG132
MOI 0.1
MCP
w/o
IE1 UL44 MCP
MOI 1
Fig. 2. Inﬂuence of MG132 on HCMV protein expression. HCMV
infected HELF (MOI 0.1 or 1) were cultured in the presence (MG132)
or absence (w/o) of 0.5 lM MG132 for 72 h and subjected to
immunoﬂuorescence using antibodies against IE1, pUL44 and MCP.
Actin
MCP
Fig. 3. HCMV protein expression in MG132 treated cells is MOI-
dependent. HELF were mock- or HCMV infected (MOI 0.1–2) and
cultured with or without 0.5 lMMG132. At 72 h p.i. cell extracts were
subjected to Western blot analysis using antibodies against IE1/IE2,
pUL44, pp65, gB and MCP. Membranes were re-probed for b-actin to
verify equal loading. Arrows indicate the position of proteins.0.5 lM), DNA of infected HELF (MOI 1) was separated by
PFGE and stained with ethidium bromide. PFGE analysis
showed that cleavage of concatemeric DNA into unit-length
genomes occurs in the presence of low MG132 concentrations
(60.15 lM) (Fig. 4A, lanes 4–6). However, increasing MG132
concentrations (P0.25 lM) resulted in loss of unit-length gen-
omes (Fig. 4A, lanes 7–8). These data indicated that high con-
centrations of MG132 inhibit viral DNA cleavage.
3.7. MG132 prevents viral DNA replication
To determine whether any DNA replication occurs in the
presence of MG132 we performed analyses using the nucleo-
side BrdU. Due to the virus-host shut-oﬀ in HCMV infected
cells BrdU is preferably incorporated into newly synthesized
viral DNA. HCMV infected HELF (MOI 1) were cultured
with or without MG132 (0.05–0.5 lM) for 45 h before adding
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Fig. 4. Analysis of viral DNA cleavage and de novo DNA synthesis. (A) HELF were mock- or HCMV infected (MOI 1) and cultured in the absence
(w/o) or presence of the indicated MG132 concentrations. At 72 h p.i. cells were harvested for PFGE. Lambda Ladder PFG Marker was used to
determine the size of HCMV genome monomers. (B) HCMV infected HELF (MOI 1) were cultured with the indicated MG132 concentrations or
with solvent alone (EtOH) for 45 h before adding 10 lM BrdU. At 72 h p.i. cells were subjected to immunoﬂuorescence using mAb a-BrdU.
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Untreated cells showed a BrdU staining pattern of bright
nuclear patches (Fig. 4B). This localization is consistent with
ongoing viral DNA replication. Conversely BrdU staining
was clearly reduced in the presence of MG132 and restricted
to small dot-like areas in the nucleus (Fig. 4B), indicating that
MG132 strongly inhibits viral DNA synthesis, hence causing
an early block in viral maturation.
3.8. Role of ND10 components in the anti-HCMV eﬀect of
MG132
The observation that IE expression was sensitive to protea-
some inhibition at low but not at high MOI led us to the
question whether Nuclear Domain 10 (ND10) components
including PML or hDaxx could be involved in the anti-HCMVeﬀect of MG132. Moreover, Saﬀert and Kalejta reported that
stabilization of hDaxx by proteasome inhibitors blocks IE pro-
tein expression at low but not at high MOI [17]. To address
this question we determined the inﬂuence of shRNA targeting
hDaxx and PML [18] on IE1 expression. shRNA expressing
HFF (hDaxx-kd, PML-kd cells) were infected at MOI 0.003
and treated with 0.5 lM MG132 or left untreated. HFF with
integrated vector sequence (vector) or non-functional shRNA
(siC) [18] served as control and were treated in the same
way. At 24 h p.i. IE1 expression was analyzed by immunoﬂu-
orescence.
IE1 expression was still sensitive to MG132 in the absence of
PML and hDaxx (Fig. 5A). Interestingly, the number of IE1-
positive cells in MG132 treated PML-kd and hDaxx-kd HFF
was slightly increased compared to control HFF (Fig. 5A),
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Fig. 5. Target analysis of MG132. (A) PML-kd HFF (siPML2),
hDaxx-kd HFF (siDaxx1) and control HFF (vector, siC) were infected
with HCMV AD169 at MOI 0.003 and treated with 0.5 lM MG132
(MG132) or left untreated (w/o). At 24 h p.i. cells were analyzed for
IE1 expression using immunoﬂuorescence. (B) HELF were infected
with HCMV AD169 BACmids HB5 or HB5DNFjB at MOI 0.001 and
analyzed for viral replication in the presence of the indicated MG132
concentrations using plaque assays. Error bars represent ± S.D. of
three independent experiments.
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functions [19,20]. However, knockdown of these proteins did
not abrogate the anti-HCMV eﬀect of MG132 suggesting
the existence of additional viral targets for proteasome inhibi-
tors.
3.9. Eﬀect of MG132 on replication of an HCMV NFjB null
mutant
NFjB is known to stimulate transcription of IE genes due to
four NFjB binding sites within the MIE enhancer/promoter
[21]. Pro¨sch et al. previously established the hypothesis that sup-
pression of HCMV replication byMG132 results from blocking
NFjB activation [6]. In order to test this hypothesis we per-
formed plaque assays using the HCMV AD169 BACmid HB5
and the mutant HB5DNFjB in which all four NFjB binding
sites are abolished by site directed mutagenesis. If the antiviral
eﬀect of MG132 is caused by blocking NFjB activation, thismutant should be resistant to proteasome inhibition. However,
replication ofHB5DNFjBwas suppressed byMG132 (Fig. 5B),
suggesting that the block of viral replication is achieved via a
diﬀerent mechanism than inhibition of NFjB activation.4. Discussion
It was recently demonstrated that proteasome inhibitors
suppress HCMV replication [6]. On the basis of this observa-
tion, we further explored the role of the proteasome in HCMV
replication. Since most proteasome inhibitors also block other
cellular proteases [22], we wanted to conﬁrm that speciﬁcally
20 S proteasome activity is required for virus replication. Lact-
acystin, the most speciﬁc proteasome inhibitor known was
shown to inhibit viral replication. Conversely, calpain inhibi-
tors did not block viral replication, suggesting that it is inhibi-
tion of the proteasome that causes suppression of HCMV
replication by MG132.
Further evidence for the importance of the proteasome
during HCMV replication was obtained by analyzing 20 S pro-
teasome activity in infected HELF. Proteasome activity in-
creased in infected HELF, which might be beneﬁcial for
HCMV as it could lead to a rapid turnover of viral or cellular
proteins required for viral replication.
To determine the stage of viral replication that is sensitive to
proteasome inhibition we performed a time-of-addition study
with MG132. Interestingly, all phases of viral replication
turned out to be sensitive to MG132 treatment. The most
noticeable eﬀect was observed when the inhibitor was added
in the IE or E phase. However, even if MG132 was added at
late times post infection, viral replication was reduced by
approximately 50%. Thus, proteasome activity seems to be
required at multiple steps in HCMV replication.
We also assessed whether viral replication is still accom-
plished in the presence of proteasome inhibitors by electron
microscopy analyses. However, neither infectious nor non-
infectious viral particles were detected in MG132 treated sec-
tions, indicating a complete breakdown in virus assembly.
Subsequently we investigated whether this block was caused
by suppression of viral protein expression using immunoﬂuo-
rescence and Western blot analyses. Expression of late struc-
tural proteins including MCP and gB was completely
abolished at both high and low MOI, thus explaining the
absence of progeny virus.
In contrast to the results observed with L proteins, IE pro-
tein expression was suppressed at low MOI; however, this
repression was abolished at MOI 1. Our observations are con-
sistent with a report from Saﬀert et al. showing that stabiliza-
tion of hDaxx by proteasome inhibitors blocks IE1 expression
at low but not at high MOI [17]. However, we showed that IE1
expression remained sensitive to proteasome inhibition in HFF
with a stable knockdown of hDaxx and PML, respectively,
suggesting the existence of other targets which have an addi-
tional impact on viral replication.
Expression of early proteins was severely aﬀected by MG132
at both low and high MOI. Using immunoﬂuorescence
staining against pUL44, we observed only pre-replication
compartments in the presence of MG132, indicating a block
in viral replication. To verify this result, incorporation studies
of BrdU into newly synthesized viral DNA were carried out.
These studies showed that de novo DNA synthesis was
672 M. Kaspari et al. / FEBS Letters 582 (2008) 666–672strongly inhibited by MG132. Using PFGE we analyzed
whether MG132 also has an inﬂuence on DNA packaging.
Interestingly, MG132 inhibited cleavage of concatemeric viral
DNA in a concentration-dependent manner.
In order to identify the underlying mechanism we investi-
gated the role of NFjB in the anti-HCMV eﬀect of MG132.
Plaque assays were performed using the HCMV mutant
HB5DNFjB carrying a deletion of the four NFjB binding
sites in the MIE enhancer/promoter. However, replication of
this mutant was still sensitive to proteasome inhibition. Our
results indicate that inhibition of NFjB activation is not the
mode of action for proteasome inhibitors in HCMV replica-
tion.
In summary, these results indicate that proteasome activity
is required for multiple steps in viral replication, thus repre-
senting a new target for antiviral therapy. Further analyses
would aim to identify both the key protein whose stabilization
by proteasome inhibitors blocks viral replication and the cor-
responding E3 ubiquitin ligase. By inhibiting the particular E3
enzyme, interference with HCMV replication would be more
speciﬁc and unwanted side eﬀects could be avoided.
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